IP Library Granted Patent US 12,465,232
Granted Patent B2
US 12,465,232 · App. 18/165,096 · Granted Nov 11, 2025

Method and system for monitoring brain function and intracranial pressure

Inventor: Matthew Lyon (North Augusta, SC)
Assignee: Augusta University Research Institute, Inc.
A61B5/031A61B5/0024A61B5/369A61B5/6803A61B5/6814A61B5/743
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,232
App. No.
18/165,096
Granted
Nov 11, 2025
Kind
B2
Abstract

Embodiments of the present systems and methods may provide improved, automated monitoring of brain function. In embodiments, a multimodal, multi-sensor monitoring device may provide to monitoring of the full spectrum of brain function. In an embodiment, a system for monitoring brain function of a subject may include an apparatus for mounting a plurality of stimulus and response sensors on a head of the subject, including a cognizance stimuli-sensor suite, a physiologic sensor suite, and advance monitoring devices such as a transcranial Doppler puck, an electroencephalograph monitor, and an optic nerve sheath parameter sensor.

Claims (28)

1 . A portable system for monitoring brain function of a subject, comprising:

an apparatus configured for mounting a plurality of stimulus devices and a plurality of response sensors on a head of the subject, the plurality of stimulus devices including at least one cognizance stimulus device selected from a speaker to provide auditory stimuli to the subject and fall an internal display to provide visual stimuli to the subject, and the plurality of response sensors including at least one cognizance sensor selected from a microphone to record sounds made by the subject, a camera to record eye position and movement of the subject, and a touch/motion sensor to receive input from the subject;

a processor and memory for executing and storing program instructions to provide stimuli to the subject using the plurality of stimulus devices, to receive responses of the subject recorded by the plurality of response sensors, and to process the received responses to generate response information; and

an external display mounted to the apparatus and configured to display the generated response information.

2 . The system of claim 1 , further comprising communications circuitry to transmit the received responses and the generated response information and to receive information relating to stimuli to be provided to the subject.

3 . The system of claim 1 , wherein the plurality of response sensors further includes at least one physiological sensor selected from a vibration sensor, a heart rate monitor, a blood oxygen saturation sensor, a temperature sensor, a head position sensor, and a vibration microphone.

4 . The system of claim 1 , further comprising a vibration sensor configured to remove background vibration artifacts from signals received at the plurality of response sensors.

5 . The system of claim 1 , further comprising at least one of a transcranial Doppler device, an electroencephalograph monitor device, and an optic nerve sheath diameter measurement device.

6 . The system of claim 1 , further comprising an optic nerve sheath diameter measurement device that comprises a two-dimensional array of ultrasonic transducers to scan across the optic nerve sheath, wherein

the processor is configured for receiving and processing data obtained from the two-dimensional array of ultrasonic transducers, calculating volumes of segments of an optical nerve sheath of a subject, and producing a three-dimensional image of the optical nerve sheath on the external a graphical display in communication with the processor.

7 . The system of claim 6 , wherein the processer stores an algorithm for calculating the volume of segments of the optic nerve sheath.

8 . The system of claim 6 , wherein the two-dimensional array of ultrasonic transducers comprises lights for aligning the ultrasonic transducers with the optic nerve sheath.

9 . The system of claim 1 , wherein the apparatus is a pair of goggles.

10 . A portable telemedicine system for monitoring brain function of a subject, comprising:

a wearable platform comprising a plurality of stimulus devices, a plurality of response sensors, and an external display screen each mounted to the wearable platform, wherein the plurality of stimulus devices comprise a speaker to provide auditory stimuli to the subject and an internal display to provide visual stimuli to the subject, and the plurality of response sensors comprise a microphone to record sounds made by the subject, a camera to record eye position and movement of the subject, and a touch/motion sensor to receive input from the subject, and wherein the external display screen is configured to display information received at the plurality of response sensors; and

a processor and memory for executing and storing program instructions to provide stimuli to the subject using the plurality of stimulus devices, to receive responses of the subject recorded by the plurality of response sensors, and to process the received responses to generate response information.

11 . The system of claim 10 , further comprising communications circuitry to transmit the received responses and the generated response information and to receive information relating to stimuli to be provided to the subject.

12 . The system of claim 10 , wherein the plurality of response sensors further includes at least one physiological sensor selected from a vibration sensor, a heart rate monitor, a blood oxygen saturation sensor, a temperature sensor, a head position sensor, and a vibration microphone.

13 . The system of claim 10 , further comprising a vibration sensor configured to remove background vibration artifacts from signals received at the plurality of response sensors.

14 . The system of claim 10 , wherein the plurality of response sensors are used to monitor the subject's level of consciousness.

15 . The system of claim 10 , further comprising at least one of a transcranial Doppler device, an electroencephalograph monitor device, and an optic nerve sheath diameter measurement device.

16 . The system of claim 15 , wherein the transcranial Doppler device, the electroencephalograph monitor device, and the optic nerve sheath diameter measurement device are only activated after the subject has been determined to be unconscious.

17 . A method for automatic monitoring of brain function in a subject in need thereof, utilizing the system of claim 10 , comprising,

placing the wearable platform onto the head of the subject in need of monitoring,

providing stimuli to the subject through one of the plurality of stimulus devices,

recording the subject's response or lack of response to the stimuli, and

displaying the subject's response on the external display screen.

18 . The method of claim 17 , wherein the subject is in a mass casualty environment, is being transported, or is undergoing surgery.

Continuity (3)
Continuation 16562776 · Sep 6, 2019
Provisional Application 62728175 · Sep 7, 2018
Related Publication 20230181053A1 · Jun 15, 2023
References Cited (142)
US 5190929A · Borch et al. · 1993 [cited by applicant]
US 6387051B1 · Ragauskas et al. · 2002 [cited by applicant]
US 6395876B1 · Munn et al. · 2002 [cited by applicant]
US 6451840B1 · Munn et al. · 2002 [cited by applicant]
US 6949535B2 · Sadhu et al. · 2005 [cited by applicant]
US 8535656B2 · Kabanov et al. · 2013 [cited by applicant]
US 8546082B2 · Hall et al. · 2013 [cited by applicant]
US RE44599E · Fowler et al. · 2013 [cited by applicant]
US 8672851B1 · Quirk et al. · 2014 [cited by applicant]
US 9101279B2 · Ritchey · 2015 [cited by examiner]
US 9398861B2 · Bellezza et al. · 2016 [cited by applicant]
US 9460744B1 · Gaub · 2016 [cited by examiner]
US 9606120B2 · Bettsworth et al. · 2017 [cited by applicant]
US 10405374B2 · Zhu · 2019 [cited by examiner]
US 10856803B1 · Guez · 2020 [cited by examiner]
US 10863940B2 · Gazzaley · 2020 [cited by examiner]
US 10888241B2 · Siwoff · 2021 [cited by examiner]
US 10901508B2 · Laszlo · 2021 [cited by examiner]
US 11311188B2 · Hooriani · 2022 [cited by examiner]
US 20070202077A1 · Brodsky et al. · 2007 [cited by applicant]
US 20100135900A1 · Cerveny et al. · 2010 [cited by applicant]
US 20110135655A1 · Katsikis et al. · 2011 [cited by applicant]
US 20120010229A1 · MacDougall et al. · 2012 [cited by applicant]
US 20130012802A1 · Horseman · 2013 [cited by examiner]
US 20130150684A1 · Cooner · 2013 [cited by applicant]
US 20140163333A1 · Horseman · 2014 [cited by examiner]
US 20150051489A1 · Caluser et al. · 2015 [cited by applicant]
US 20150148681A1 · Abreu · 2015 [cited by examiner]
US 20150199010A1 · Coleman · 2015 [cited by examiner]
US 20160000354A1 · Hagedorn · 2016 [cited by examiner]
US 20160000367A1 · Lyon · 2016 [cited by examiner]
US 20160051669A1 · Khleif et al. · 2016 [cited by applicant]
US 20160213301A1 · Port · 2016 [cited by examiner]
US 20160246373A1 · Sakaguchi · 2016 [cited by examiner]
US 20160262687A1 · Vaidyanathan · 2016 [cited by examiner]
US 20170252216A1 · Maeda · 2017 [cited by examiner]
US 20170296421A1 · Travers · 2017 [cited by examiner]
US 20170347906A1 · Intrator · 2017 [cited by examiner]
US 20180103894A1 · Tzvieli · 2018 [cited by examiner]
US 20180103917A1 · Kim · 2018 [cited by examiner]
US 20180132739A1 · Brekken · 2018 [cited by examiner]
US 20180279934A1 · Wo · 2018 [cited by examiner]
US 20180280656A1 · Cole · 2018 [cited by examiner]
US 20180296191A1 · Mellema · 2018 [cited by examiner]
US 20180310855A1 · Connor · 2018 [cited by examiner]
US 20180333092A1 · Roshan · 2018 [cited by examiner]
US 20190008441A1 · Guzik · 2019 [cited by examiner]
US 20190019336A1 · Coggins · 2019 [cited by examiner]
US 20190038166A1 · Tavabi · 2019 [cited by examiner]
US 20190059769A1 · Nenadovic · 2019 [cited by examiner]
US 20190059821A1 · Pekonen · 2019 [cited by examiner]
US 20190134395A1 · Fitzgerald · 2019 [cited by examiner]
US 20190142270A1 · Monhart · 2019 [cited by examiner]
US 20190307350A1 · Sridhar · 2019 [cited by examiner]
US 20190369726A1 · Kang · 2019 [cited by examiner]
US 20200029819A1 · Yamada · 2020 [cited by examiner]
US 20200029851A1 · Siwoff · 2020 [cited by examiner]
US 20200060573A1 · Cohen · 2020 [cited by examiner]
US 20200069209A1 · Keane · 2020 [cited by examiner]
US 20200139112A1 · Aharonovitch · 2020 [cited by examiner]
US 20210093247A1 · Pyrzowski · 2021 [cited by examiner]
US 20210141453A1 · Miller, III · 2021 [cited by examiner]
US 20210145450A1 · Gruentzig · 2021 [cited by examiner]
WO 2004084933A1 · 2004 [cited by applicant]
WO 2008147482A2 · 2008 [cited by applicant]
WO 2012037204A1 · 2012 [cited by applicant]
Hayreh, et al., “The role of optic nerve sheath fenestration in management of anterior ischemic optic neuropathy,” Arch Opthalmol., 108(8):1063-1065 (1990). [cited by applicant]
Killer et al., “Architecture of arachnoid trabeculae, pillars, and septa in the subarachnoid space of the human optic nerve: anatomy and clinical considerations,” Br J Opthamol, 87(6):777-781 (2003). [cited by applicant]
Kimberly et al., “Correlation of Optic Nerve Sheath Diameter with Direct Measurement of Intracranial Pressure,” Society for Academic Emergency Medicine, 15(2), 201-204 (2008). [cited by applicant]
Bach, “The effect of Infections on susceptibility to autoimmune and allergic diseases”, N. Eng. J. Med., 347:911-20 (2002). [cited by applicant]
Barka, et al., “Transduction of TAT-HA-β-galactosidase fusion protein into salivary gland-derived cells and organ cultures of the developing gland, and into rat submandibular gland in vivo”, Histochem. Cytochem., 48(11)… [cited by applicant]
Bernstein, et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”, Nature, 409:363-6 (2001). [cited by applicant]
Bluestone, et al., “Natural versus adaptive regulatory T cells”, Nat Rev Immunol, 3:253-7 (2003). [cited by applicant]
Boland, et al., “Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum”, Am J Hum Gene., 81 :292-303 (2007). [cited by applicant]
Carson, et al., “Impaired T cell receptor signaling in Foxp3+ CD4 T cells”, Ann NY Acad Sci., 1103:167-78 (2007). [cited by applicant]
Crellin, et al., “Altered activation of AKT is required for the suppressive function of human CD4 [cited by applicant]
Crellin, et al., “Flow cytometry-based methods for studying signaling in human CD4 [cited by applicant]
Dannull, et al., “Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells”, J Clin Invest., 115:3623-33 (2005). [cited by applicant]
DeBosch, et al., “Akt2 regulates cardiac metabolism and cardiomyocyte survival”, J. Biol. Chem, 281:32841-51 (2006). [cited by applicant]
Derossi, et al., “The third helix of the Antennapedia homeodomain translocates through biological membranes”, J. Biol. Chem., 269(14):10444-50 (1994). [cited by applicant]
Elbashir, et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature, 411:494-8 (2001b). [cited by applicant]
Elbashir, et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”, Genes Dev., 15:188-200 (2001). [cited by applicant]
Emamian, et al., “Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia”, Nat Genet, 36:131-137 (2004). [cited by applicant]
Final Rejection mailed May 23, 2018 for U.S. Appl. No. 14/832,915 (8 pgs). [cited by applicant]
Final Rejection mailed Oct. 10, 2019 for U.S. Appl. No. 14/832,915 (7 pgs). [cited by applicant]
Fire, et al., “Potent and specific genetic interference by double-stranded RNA in [cited by applicant]
Fontenot, et al., “Foxp3 programs the development and function of CD4 [cited by applicant]
Fousteri, et al., “Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ”, Diabetologia, 53:1958-70 (2010). [cited by applicant]
Franke “Intracellular signaling by Akt: bound to be specific” , Science 1 (24):pe29: 1-4 (2008). [cited by applicant]
Frankel and Pabo, “Cellular uptake of the tat protein from human immunodeficiency virus”, Cell, 55(6):1189-93 (1988). [cited by applicant]
Furman et al., 2010, Blood, vol. 116: Abstract 55 (3 pgs). [cited by applicant]
Garofalo, et al., “Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ”, J Clin Invest., 112:197-208 (2003). [cited by applicant]
Genbank, Accession No. Y10055.2, “ [cited by applicant]
George, et al., “A family with severe insulin resistance and diabetes due to a mutation in AKT2”, Science, 304:1325-8 (2004). [cited by applicant]
Glisic, et al., “Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls”, Cell and Tissue Research, 339:585-95 … [cited by applicant]
Hammond, et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing in [cited by applicant]
Hannon, “RNA interference”, Nature, 418:244-51 (2002). [cited by applicant]
Haribhai, et al., “A requisite role for Induced regulatory T cells in tolerance based on expanding antigen receptor diversity”, Immunity, 35(1):109-122 (2011). [cited by applicant]
Haxhinasto, “The AKT-mTOR axis regulates de nova differentiation of CD4 [cited by applicant]
Hayashi, et al., “Inhibition of experimental asthma by indoleamine 2,3-dioxygenase”, J. Clin. Investig., 114(2):270-279 (2004). [cited by applicant]
Ho, et al., “Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo”, Cancer Res., 61(2):474-7 (2001). [cited by applicant]
Ho, et al., “Tolerizing DNA vaccines for autoimmune arthritis”, Autoimmunity, 39(8):675-82 (2006). [cited by applicant]
Hori, et al., “Control of regulatory T cell development by the transcription factor Foxp3”, Science, 299:1057-61 (2003). [cited by applicant]
Hyrup, et al., “Peptide nucleic acids (PNA): synthesis, properties and potential applications”, Bioorgan. Med. Chem., 4:5-23 (1996). [cited by applicant]
Ilan, “Oral tolerance: can we make it work”, Human Immunol., 70:768-76 (2009). [cited by applicant]
Johnson, et al., “Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy”, Immunotherapy, 1(4):645-661 (2009). [cited by applicant]
Kabouridis, “Biological applications of protein transduction technology”, Trends in Biotechnology (11):498-503 (2003). [cited by applicant]
Khattri, et al., “An essential role for Scurfin in CD4 [cited by applicant]
Kim et al., “Natural and inducible T [cited by applicant]
Li, et al., “CD4 [cited by applicant]
Liang, et al., “Design of new oxazaphosphorine anticancer drugs”, Curr Pharm Des., 13(9):963-78 (2007). [cited by applicant]
Martinez, et al., “Single-stranded antisense siRNAs guide target RNA cleavage in RNAi”, Cell, 110:563-74 (2002). [cited by applicant]
Nakatani, et al., “Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines”, J Biol Chem., 274:21528-32 (1999). [cited by applicant]
Napoli, et al., “Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans”, Plant Cell, 2:279-89 (1990). [cited by applicant]
Non-Final Rejection mailed Jun. 9, 2020 for U.S. Appl. No. 14/832,915 (7 pgs). [cited by applicant]
Non-Final Rejection mailed Mar. 29, 2019 for U.S. Appl. No. 14/832,915 (6 pgs). [cited by applicant]
Non-Final Rejection mailed Nov. 9, 2017 for U.S. Appl. No. 14/832,915 (8 pgs). [cited by applicant]
Nykänen, et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway”, Cell, 107:309-21 (2001). [cited by applicant]
Parry, et al., “Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation”, Trends Immunol., 28:161-168 (2007). [cited by applicant]
Patton, et al., “Cutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25 Foxp3+ regulatory T cells”. J. Immunol., 177:6598-602 (2006). [cited by applicant]
Patton, et al., “The PI3K p110 delta controls T-cell development, differentiation and regulation”, Biochem. Soc. Trans., 35:167-171 (2007). [cited by applicant]
Requirement for Restriction/Election Mailed Jun. 15, 2017 for U.S. Appl. No. 14/832,915 (8 pgs). [cited by applicant]
Rommel, et al., “P13Kδ and P13Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond”, Nat Rev Immunol., 7:191-201 (2007). [cited by applicant]
Sakaguchi, “Regulatory T cells: key controllers of immunologic self-tolerance”, Cell, 101:455-8 (2000). [cited by applicant]
Sakaguchi, et al., “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases”, J. Immunol.… [cited by applicant]
Sakaguchi, et al., “Regulatory T cells and immune tolerance”, Cell, 133:775-87 (2008). [cited by applicant]
Sakagushi, et al., “Foxp3 [cited by applicant]
Sakagushi, et al., “Naturally arising Foxp3-expressing CD25 [cited by applicant]
Sauer, et al., “T cell receptor signaling controls Foxp3 expression via P13K, Akt, and mTOR”, PNAS, 105:7797-802 (2008). [cited by applicant]
Schmidt, et al., “Molecular mechanisms of treg-mediated T cell suppression”, Front Immunol., 3:51:1-20 (2012). [cited by applicant]
Summerton and Weller, “Morpholino antisense oligomers: design, preparation, and properties”, Antisense Nucleic Acid Drug Dev. 7:187-195 (1997). [cited by applicant]
Tschopp, et al., “Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis”, Development., 132:2943-2954 (2005). [cited by applicant]
Tsiperson, et al., “Suppression of inflammatory responses during myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis is regulated by AKT3 signaling”, J Immunol., 190(4):1528-39 (2013). [cited by applicant]
Ui-Tei, et al., “Sensitive assay of RNA interference in [cited by applicant]
UniProtKB/Swiss-Prot accession No. 000329, “RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Short=P13-kinase subunit delta; Short=P13K-delta; Short=P13Kdelta; Short . . . Pt… [cited by applicant]
Wadia, et al., “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft micropinocytosis”, Nat Med., 10(3):310—May 2004). [cited by applicant]
Walsh, et al., “PTEN inhibits IL-2 receptor-mediated expansion of CD4 [cited by applicant]
Wender, et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters”, PNAS., 97(24 ): 13003-8 (2000). [cited by applicant]
Xiao, et al., “Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases”, Clin. Immunol. Immunopath., 85(2):119-28 (1997). [cited by applicant]
Yang, et al., “Protein kinase Bα/Akt1 regulates placental development and fetal growth”, J. Biol. Chem., 278:32124-32131 (2003). [cited by applicant]
Ronco, et al. (Eds.), “Kidney Transplantation: Strategies to Prevent Organ Rejection”. Contributions to Nephrologhy. vol. 146. S. Karger A.G. pp. 1-155 (2005). [cited by applicant]
Non-Final Rejection mailed Aug. 8, 2022 for U.S. Appl. No. 16/562,776 (18 pgs). [cited by applicant]